Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor
To the Editor: The 3-year, randomized controlled
trial reported by Dr Harris and colleagues1
demonstrated that risedronate increased bone mineral density and decreased
fracture incidence in postmenopausal women with established osteoporosis.
Although the overall safety profile was similar in the placebo and risedronate
groups, serious adverse events were more common in the treatment group.
Goldstein MR. Bisphosphonate Therapy and Vascular Calcification. JAMA. 2000;283(11):1424-1425. doi:10.1001/jama.283.11.1421